What is the address of LENAPHARM?

The registered office of LENAPHARM is located at Generaal Jacqueslaan 42 box 1, 1050 Elsene.

Is LENAPHARM still active?

Yes. According to the CBE (5 October 2026) LENAPHARM is active, legal situation “Normale toestand”, started on 28 July 2014.

Is LENAPHARM registered on Peppol?

Yes, LENAPHARM is registered on the Peppol network with ID 0208:0556895014.

What is the enterprise number of LENAPHARM?

The enterprise number of LENAPHARM is BE0556895014.

When was LENAPHARM founded?

LENAPHARM was founded on 28 July 2014.

Is LENAPHARM a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 28 July 2014; 4 annual accounts filed, latest fiscal year 2024.

How much profit did LENAPHARM make in 2024?

LENAPHARM posted a profit after taxes of € 6,522 in financial year 2024.

What is the revenue of LENAPHARM?

As a small company, LENAPHARM is not required to publish revenue in its annual accounts. In financial year 2024, its added value was € 59,355.

LENAPHARM (Private Limited) - Elsene - BE0556895014

Dossier LENAPHARM, printed on 5 October 2026 from databakkes.be/en/0556895014/lenapharm. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 28 % of short-term debt in 2024; threshold 65 %.

Financials

Financial year 2024

LENAPHARM from Elsene, company number BE0556895014, closed financial year 2024 with a result of € 6,522 after tax. For that financial year LENAPHARM recorded a gross margin of € 59,355 and equity of € 119,486. Compared with financial year 2023, the result moved from € 5,760 to € 6,522. Profitable, and profit is growing. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on October 18, 2025.

What it is worth Growing

€ 119,486

▲ 6% vs 2023

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 6,522

▲ 13% vs 2023

Profit after tax over the fiscal year.

Cash in the bank

€ 23

▼ 96% vs 2023

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2024. Retained profit grew to € 100,886.

Debts at end 2024

Bank debt ≈ 4 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 239,375

▼ 15% vs 2023

€ 53,762 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.

Owed to suppliers

€ 21,201

▲ 52% vs 2023

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 54,813

▲ 32% vs 2023

Taxes, VAT and social contributions still to pay.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2021	2022	2023	2024	Change 2023 → 2024
Gross margin	€ 21,050 Gross margin 2021: € 21,050 First fiscal year in the series	€ 37,994 Gross margin 2022: € 37,994 ▲ 80% vs 2021 (€ 21,050) Favourable step	€ 15,966 Gross margin 2023: € 15,966 ▼ 58% vs 2022 (€ 37,994) Unfavourable step	€ 59,355 Gross margin 2024: € 59,355 ▲ 272% vs 2023 (€ 15,966) Favourable step	▲ 272%
Profit after taxes	€ 4,460 Profit after taxes 2021: € 4,460 First fiscal year in the series	€ 21,110 Profit after taxes 2022: € 21,110 ▲ € 16,650 vs 2021 (€ 4,460) Favourable step	€ 5,760 Profit after taxes 2023: € 5,760 ▼ 73% vs 2022 (€ 21,110) Unfavourable step	€ 6,522 Profit after taxes 2024: € 6,522 ▲ 13% vs 2023 (€ 5,760) Favourable step	▲ 13%
Equity	€ 86,093 Equity 2021: € 86,093 First fiscal year in the series	€ 107,203 Equity 2022: € 107,203 ▲ 25% vs 2021 (€ 86,093) Favourable step	€ 112,963 Equity 2023: € 112,963 ▲ 5% vs 2022 (€ 107,203) Favourable step	€ 119,486 Equity 2024: € 119,486 ▲ 6% vs 2023 (€ 112,963) Favourable step	▲ 6%
Total debts	€ 1,054,861 Total debts 2021: € 1,054,861 First fiscal year in the series	€ 866,339 Total debts 2022: € 866,339 ▼ 18% vs 2021 (€ 1,054,861) Favourable step	€ 924,132 Total debts 2023: € 924,132 ▲ 7% vs 2022 (€ 866,339) Unfavourable step	€ 944,188 Total debts 2024: € 944,188 ▲ 2% vs 2023 (€ 924,132) Unfavourable step	▲ 2%
Cash	€ 1,610 Cash 2021: € 1,610 First fiscal year in the series	€ 879 Cash 2022: € 879 ▼ 45% vs 2021 (€ 1,610) Unfavourable step	€ 588 Cash 2023: € 588 ▼ 33% vs 2022 (€ 879) Unfavourable step	€ 23 Cash 2024: € 23 ▼ 96% vs 2023 (€ 588) Unfavourable step	▼ 96%
Retained profit	€ 67,493 Retained profit 2021: € 67,493 First fiscal year in the series	€ 88,603 Retained profit 2022: € 88,603 ▲ 31% vs 2021 (€ 67,493) Favourable step	€ 94,363 Retained profit 2023: € 94,363 ▲ 7% vs 2022 (€ 88,603) Favourable step	€ 100,886 Retained profit 2024: € 100,886 ▲ 7% vs 2023 (€ 94,363) Favourable step	▲ 7%
Bank debt	€ 369,953 Bank debt 2021: € 369,953 First fiscal year in the series	€ 326,192 Bank debt 2022: € 326,192 ▼ 12% vs 2021 (€ 369,953) Favourable step	€ 281,223 Bank debt 2023: € 281,223 ▼ 14% vs 2022 (€ 326,192) Favourable step	€ 239,375 Bank debt 2024: € 239,375 ▼ 15% vs 2023 (€ 281,223) Favourable step	▼ 15%
Balance sheet total	€ 1,140,955 Balance sheet total 2021: € 1,140,955 First fiscal year in the series	€ 973,542 Balance sheet total 2022: € 973,542 ▼ 15% vs 2021 (€ 1,140,955) Unchanged	€ 1,037,096 Balance sheet total 2023: € 1,037,096 ▲ 7% vs 2022 (€ 973,542) Unchanged	€ 1,063,674 Balance sheet total 2024: € 1,063,674 ▲ 3% vs 2023 (€ 1,037,096) Unchanged	▲ 3%

Key figures of LENAPHARM, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.

What happened to LENAPHARM?

What happened at LENAPHARM in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Oct 18, 2025 New annual accounts for financial year 2024: profit of € 6,522 (▲ 13% vs 2023). filed late Source: NBB ↗
Jul 28, 2014 New establishment in Elsene. KBO
Jul 28, 2014 Start of the company according to the CBE. KBO

In short

From € 4,460 profit in 2021 to € 6,522 profit in 2024.

Paid € 12,883 in corporate taxes since 2021.

Best year ever: 2022, with € 21,110 profit.

Original PDFs at the National Bank ↗

A new publication or filing at LENAPHARM? We notify you, reason included.

Follow LENAPHARM

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Establishments

Establishment units

Physical locations of this company

Registered office

Generaal Jacqueslaan 42 box 1

1050 Elsene

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 3 companies are registered at this address.

All companies at this address →

SEA & SPACE EXPLORATION

€ 86,438 gross margin · 2025

The River Of Life

LENAPHARM PHARMACIE

€ 151,233 gross margin · 2024

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0556.895.014
VAT number: BE 0556.895.014
Registered office: Generaal Jacqueslaan 42 bus 1, 1050 Elsene
Names & denominations: LENAPHARM
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 28 July 2014
Peppol: Active · Active since 14 Nov 2025

View on CBE Public ↗ Annual accounts (NBB) ↗

LENAPHARM